FSRH CEU response public consult desogestrel POP as pharmacy medicine - Feb 2021


Published on: 18 February 2021

File size: 380kb PDF

File type: FSRH Response

This statement is a FSRH CEU response to a public consultation conducted by the Medicines and Healthcare products Regulatory Agency (MHRA) regarding licensing of two brands of desogestrel 75mcg progestogen-only pill (POP) as Pharmacy Medicines (P). The products are Hana® (Laboratoire HRA Pharma) and Lovima® (Maxwellia Ltd).

Your download should start automatically. If not download directly.